• Corpus ID: 43296531

Optimizing dosage regimen for FP 3 based on vascular normalization window monitored by ratio of Ang-1 to Ang-2

@inproceedings{Guan2017OptimizingDR,
  title={Optimizing dosage regimen for FP 3 based on vascular normalization window monitored by ratio of Ang-1 to Ang-2},
  author={Zhonghai Guan and Xiangheng Chen and Xiaoxia Jiang and Zhongqi Li and Xiongfei Yu and Ketao Jin and Jiang Cao and Lisong Teng},
  year={2017}
}
Vascular normalization explained the successful efficacy of combined antiangiogenic and cytotoxic therapy. The optimal dosage regimen of anti-VEGF therapy to achieve a maximized efficacy and a minimized toxicity response needs further investigations based on vascular normalization monitoring. FP3 (also referred to as Conbercept, KH902 or Fusion protein III, developed by KanghongBiotechnology, China) is a novel anti-VEGF agent, which has been demonstrated to have a stable effect on… 

Figures and Tables from this paper

References

SHOWING 1-10 OF 32 REFERENCES
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients
TLDR
The results suggest that the clinical response to bevacizumab may occur through an increase in the extent of vascular normalization primarily in patients with a high baseline tumor microvessel density, and suggests that new therapies are needed to normalize vessels without pruning.
Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases
TLDR
It is indicated that addition of FP3 to capecitabine significantly improved tumor growth inhibition in the PDTT xenograft models of primary colon carcinoma and lymphatic and hepatic metastases.
Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab in advanced non-small-cell-lung cancer patients
TLDR
The combination of bevacizumab with a dose/dense chemotherapy regimen resulted moderately safe but showed significant anti-angiogenic, and anti-tumor activity.
Antitumor effect of FP3 in a patient-derived tumor tissue xenograft model of gastric carcinoma through an antiangiogenic mechanism.
TLDR
Investigation of the effects of FP3 on blood vessels in a patient-derived tumor tissue (PDTT) xenograft model of gastric carcinoma, using large tumors with established vasculature, revealed a direct and rapid antiangiogenic effect on tumor vessels.
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
TLDR
Improved preclinical assessment of all stages of metastatic disease should be a priority for future antiangiogenic drug discovery and development.
The Potential of Antiangiogenic Therapy in Non–Small Cell Lung Cancer
  • G. Giaccone
  • Biology, Medicine
    Clinical Cancer Research
  • 2007
TLDR
The most important findings of angiogenesis inhibitors in NSCLC are summarized and the potential for the use of these novel agents in different settings of NSCLc is discussed.
Establishment of a PDTT xenograft model of gastric carcinoma and its application in personalized therapeutic regimen selection.
TLDR
A patient-derived tumor tissue (PDTT) xenograft model of gastric carcinoma is established for personalized cancer therapeutic regimen selection and testing of novel molecularly targeted agents.
Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.
  • R. Jain
  • Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
TLDR
Current efforts are directed at identifying predictive biomarkers and more-effective strategies to normalize the tumor microenvironment for enhancing anticancer therapies.
...
1
2
3
4
...